NEOG vs CBLL vs PHG Stock Comparison

Neogen, Ceribell and Koninklijke Philips Prices as of Oct 27, 2026 Peers: Industry group
NEOG Neogen Corp
$12.47 -9.4% 1M +100.8% 1Y
Market cap
$2.72B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
CBLL Ceribell, Inc.
$27.22 +14.9% 1M +111.2% 1Y
Market cap
$1.04B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
3 wins
PHG Koninklijke Philips Nv
$26.42 +5.8% 1M -8.5% 1Y
Market cap
$25.44B
P/E
13.6x
Revenue (TTM)
$20.60B
Div. yield
3.75%
Diagnostic Equipment Healthcare
7 wins

Head to Head

10 decided of 12

Koninklijke Philips leads on 7 of the 12 questions below (Koninklijke Philips 7, Ceribell 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNEOGCBLLPHGLeader
Larger companyMarket capitalisation $2.72B $1.04B $25.44B PHG
Cheaper on earningsLower P/E, profitable companies only -48.5x -15.7x 13.6x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 39.0x — 13.3x PHG
Faster revenue growthRevenue growth, trailing twelve months -0.3% +31.7% +6.1% CBLL
More profitableNet margin, trailing twelve months -6.3% -64.7% 8.9% PHG
Better return on capitalReturn on invested capital -0.2% — 11.5% PHG
Less leveragedLower net debt / EBITDA 5.4x 1.6x 1.8x CBLL
Higher dividend yieldTrailing dividend yield — — 3.75% –
Better 1-year returnPrice return, last 12 months +100.8% +111.2% -8.5% CBLL
Better 5-year returnAnnualised price return, 5 years -21.4%/yr — -11.1%/yr PHG
Less volatileAnnualised volatility, 1 year 55.6% 52.1% 28.7% PHG
Higher overall scoreMean of the five percentile scores vs peers 58/100 38/100 80/100 PHG

Percentile Scorecard

NEOGCBLLPHG

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNEOGCBLLPHG
Valuation 71 #66 of 227 22 #178 of 227 98 #6 of 227
Growth 50 #110 of 219 22 #172 of 219 95 #11 of 219
Profitability 62 #79 of 206 38 #129 of 206 95 #11 of 206
Financial Health 46 #128 of 238 81 #46 of 238 31 #165 of 238
Shareholder Returns 58 #57 of 134 30 #94 of 134 79 #29 of 134
Overall 58 38 80
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics
  • CBLL ranked among 247 companies in Medical Devices and Diagnostics
  • PHG ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNEOGCBLLPHGSPY
1 month -9.4%+14.9%+5.8% -0.2%
3 months +35.7%+52.7%+3.4% +3.9%
6 months +33.5%+30.9%-2.6% +8.2%
Year to date +78.4%+24.1%-2.4% +12.9%
1 year +100.8%+111.2%-8.5% +12.3%
3 years -18.6%—+42.8% +87.4%
3 years, per year -6.6%—+12.6% +23.3%
5 years -69.9%—-44.3% +67.9%
5 years, per year -21.4%—-11.1% +10.9%
10 years -35.8%—-11.3% +261.1%
10 years, per year -4.3%—-1.2% +13.7%

Risk

MeasureNEOGCBLLPHGSPY
Volatility, 1Y 55.6%52.1%28.7% 12.7%
Downside volatility, 1Y 46.5%49.5%28.7% 12.7%
Beta vs S&P 500, 1Y 1.451.210.81 1.00
Return / volatility, 1Y 1.812.13-0.30 0.97
Max drawdown, 5Y -90.6%-63.9%-75.6% -25.4%
From 52-week high -10.8%-1.7%-19.7% -1.2%
52-week high $13.98$27.68$32.91 $779.14
52-week low $5.41$10.92$23.81 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNEOGCBLLPHG
P/E now vs peer median -48.5xmedian 29.6x -15.7xmedian 29.6x 13.6xmedian 29.6x
P/S now vs peer median 3.1xmedian 2.9x 10.2xmedian 2.9x 1.2xmedian 2.9x
EV/EBITDA now vs peer median 30.0xmedian 17.4x -13.6xmedian 17.4x 8.1xmedian 17.4x
P/FCF now vs peer median 54.7xmedian 22.3x -19.0xmedian 22.3x 5.9xmedian 22.3x
P/B now vs peer median 1.3xmedian 2.3x 8.1xmedian 2.3x 1.9xmedian 2.3x
PEG now vs peer median 1.73median 1.04 —median 1.04 0.32median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNEOGCBLLPHG
Revenue $883.99M $101.96M $20.60B
Gross profit $418.98M $90.65M $16.03B
Operating income -$7.38M -$69.97M $2.65B
Net income -$56.10M -$66.00M $1.39B
Free cash flow $49.80M -$54.72M $4.34B
R&D $19.76M $22.95M $2.00B
EPS (diluted) $-0.26 $-1.74 $1.91
Cash & equivalents $172.00M $32.66M $2.04B
Total debt $774.20M $19.98M $9.51B
Shares (diluted) 218.10M 38.03M 962.50M
Enterprise value $2.06B $442.19M $14.59B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNEOGCBLLPHG
P/E -48.5x -15.7x 13.6x
P/FCF 54.7x -19.0x 5.9x
P/Operating cash flow 31.9x -19.3x 9.6x
P/S 3.1x 10.2x 1.2x
P/B 1.3x 8.1x 1.9x
P/Tangible book 3.4x 8.1x 2.5x
EV/EBITDA 30.0x -13.6x 8.1x
EV/EBIT -450.7x -13.3x 12.4x
EV/Revenue 3.8x 9.1x 1.6x
EV/FCF 66.8x -17.0x 7.6x
EV/Operating cash flow 39.0x -17.2x 12.4x
PEG (3Y EPS CAGR) 1.73 – 0.32

Growth

14 metrics
MetricNEOGCBLLPHG
Revenue growth (1Y) -0.3% 31.7% 6.1%
Revenue CAGR (3Y) -1.3% – 2.3%
Gross profit growth (1Y) 1.8% 33.4% 82.4%
Gross profit CAGR (3Y) -3.1% – 6.7%
Operating income growth (1Y) 99.3% -34.6% 121.3%
Operating income CAGR (3Y) -29.0% – 52.0%
Net income growth (1Y) 94.6% -33.6% 293.5%
Net income CAGR (3Y) -28.3% – 35.6%
EPS growth (1Y) 94.6% -27.5% 539.4%
EPS CAGR (3Y) -28.0% – 42.2%
Operating cash flow growth (1Y) -1.9% -44.3% 116.7%
Operating cash flow CAGR (3Y) 2.9% – 53.6%
Free cash flow growth (1Y) 1,631% -41.8% 54.2%
Free cash flow CAGR (3Y) 126.1% – 45.6%

Profitability

14 metrics
MetricNEOGCBLLPHG
Gross margin 47.4% 88.9% 77.8%
EBITDA margin 12.5% -67.1% 19.8%
Operating margin -0.8% -68.6% 12.9%
Pretax margin -7.7% -64.7% 11.9%
Net margin -6.3% -64.7% 8.9%
FCF margin 5.6% -53.7% 21.1%
Operating cash flow margin 9.6% -53.0% 12.9%
Return on equity -2.7% -49.0% 12.7%
Return on assets -1.7% -38.3% 5.4%
Return on invested capital -0.2% – 11.5%
Return on capital employed -0.2% -45.1% 11.8%
Asset turnover 0.3x 0.6x 0.7x
Cash conversion (OCF / net income) -1.5x 0.8x 1.9x
Stock comp / revenue 1.3% 16.1% 0.7%

Financial Health

11 metrics
MetricNEOGCBLLPHG
Debt / assets 23.4% 12.0% 31.2%
Debt / equity 0.4x 0.2x 0.7x
Net debt / EBITDA 5.4x 1.6x 1.8x
Debt / FCF 15.5x -0.4x 2.2x
Liabilities / assets 36.8% 22.9% 57.1%
Equity / assets 63.2% 77.1% 42.9%
Interest coverage – -38.6x 6.2x
Current ratio 3.9x 9.2x 1.3x
Quick ratio 2.1x 8.6x 0.7x
Cash ratio 1.2x 7.5x 0.2x
Altman Z-score 1.52 14.47 –

Shareholder Returns

7 metrics
MetricNEOGCBLLPHG
Dividend yield – – 3.7%
Net buyback yield -0.1% -0.6% -0.5%
Shareholder yield -0.1% -0.6% 3.3%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNEOGCBLLPHG
Forward P/E 39.0xFY2026 – 13.3xFY2026
EPS, next fiscal year $0.32FY2026 $-1.86FY2026 $1.98FY2026
EPS growth, next FY 0.0%FY2026 – +6.5%FY2026
EPS growth, the year after +31.3% – -10.1%
Revenue, next fiscal year $847.28MFY2026 $118.32MFY2026 $21.63BFY2026
Revenue growth, next FY -2.7%FY2026 +32.9%FY2026 +1.8%FY2026
Revenue growth, the year after -1.5% +21.1% -8.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNEOGCBLLPHG
Held by institutions 100.0% 79.9% 5.4%
Institutions holding 315 124 363
Change in shares held, QoQ +1.6% +2.2% +0.8%
Institutions buying 151 74 266
Institutions selling 106 36 76
Buyers to sellers 1.42 2.06 3.50

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NEOGCBLLPHG
NEOG 1.00 0.25 0.31
CBLL 0.25 1.00 0.22
PHG 0.31 0.22 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NEOG, CBLL and PHG?

Koninklijke Philips (PHG) is the largest by market capitalisation: Neogen (NEOG) $2.72B, Ceribell (CBLL) $1.04B, Koninklijke Philips (PHG) $25.44B.

Which company is growing faster?

Ceribell (CBLL) grew revenue fastest over the trailing twelve months: Neogen (NEOG) -0.3%, Ceribell (CBLL) +31.7%, Koninklijke Philips (PHG) +6.1%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Neogen (NEOG) -6.3%, Ceribell (CBLL) -64.7%, Koninklijke Philips (PHG) 8.9%). On return on invested capital, Koninklijke Philips (PHG) leads (Neogen (NEOG) -0.2%, Koninklijke Philips (PHG) 11.5%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Neogen (NEOG) +100.8%, Ceribell (CBLL) +111.2%, Koninklijke Philips (PHG) -8.5%. Over five years, Koninklijke Philips (PHG) compounded fastest (Neogen (NEOG) -21.4%/yr, Koninklijke Philips (PHG) -11.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Koninklijke Philips (PHG) 3.75%. Neogen (NEOG) and Ceribell (CBLL) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Neogen (NEOG) 55.6%, Ceribell (CBLL) 52.1%, Koninklijke Philips (PHG) 28.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NEOG, CBLL and PHG?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.